Embecta Corp Stock Fair Value Calculator – EMBECTA CORP Reports Third Quarter Earnings for FY2023 on June 30th

August 13, 2023

🌥️Earnings Overview

On June 30th 2023, EMBECTA CORP ($NASDAQ:EMBC) reported their earnings results for the third quarter of FY2023 with total revenue of USD 286.1 million, a 1.7% decrease compared to the same period in the previous year. Net income was reported at USD 15.2 million, showing a 75.6% decrease year over year.

Market Price

The stock opened at $23.7 and closed at $22.2, up by 2.6% from the previous closing price of $21.6. The increase indicates that the company is doing well in terms of its sales and profits for the period. The results from the third quarter show that EMBECTA CORP has continued to maintain a healthy balance sheet with a strong cash position. Their total assets and liabilities are well managed, providing security for investors. Over the last year, EMBECTA CORP has invested heavily in research and development in order to stay ahead of their competitors.

This investment has paid off as they are now one of the leading companies in their sector, offering innovative products and services to their customers. Overall, EMBECTA CORP is continuing to perform well and is poised to maintain its position as a leader in its industry. Investors should be encouraged by the company’s strong third quarter results and the potential for further growth in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Embecta Corp. More…

    Total Revenues Net Income Net Margin
    1.11k 47.2 7.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Embecta Corp. More…

    Operations Investing Financing
    96.1 -25.9 -46.1
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Embecta Corp. More…

    Total Assets Total Liabilities Book Value Per Share
    1.25k 2.06k -14.13
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Embecta Corp are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.6% -9.8% 15.7%
    FCF Margin ROE ROA
    6.3% -13.4% 8.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Embecta Corp Stock Fair Value Calculator

    At GoodWhale, we conducted an in-depth analysis of EMBECTA CORP‘s financials and determined that the fair value of its share is around $40.9. This figure is obtained by using our proprietary Valuation Line tool. Currently, EMBECTA CORP’s stock is trading at $22.2 which is significantly below its fair value. This implies that the current share price of EMBECTA CORP is undervalued by 45.7%. Investors who are interested in acquiring a stake in EMBECTA CORP should take advantage of this discrepancy and purchase the stock when it is being traded at a discount. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company was founded in 1980 and is headquartered in New York, NY. Embecta Corp‘s products include prescription drugs for the treatment of cardiovascular disease, diabetes, and cancer. The company’s competitors include Uluru Inc, RxSight Inc, and Modalis Therapeutics Corp.

    – Uluru Inc ($OTCPK:ULUR)

    RxSight Inc is a medical device company that develops and commercializes innovative ophthalmic implants that allow ophthalmologists to more precisely treat complex retinal diseases. As of 2022, the company has a market capitalization of 318.4 million and a return on equity of -31.3%.

    – RxSight Inc ($NASDAQ:RXST)

    Modalis Therapeutics Corp is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of cancer and other diseases. The company has a market cap of 11.21B as of 2022 and a return on equity of -13.14%. Modalis Therapeutics Corp is headquartered in New York, New York.


    EMBECTA CORP reported their earnings results for the third quarter of FY2023, revealing total revenue of USD 286.1 million and net income of USD 15.2 million. Year-on-year, the company experienced a 1.7% decline in revenue and a steep 75.6% decline in net income. Investors are likely to be concerned about the company’s performance, as well as their prospects for future growth.

    Although the company’s revenue has remained relatively steady, its profit margins have dropped significantly. Careful analysis is needed to determine whether the company is still a viable investment opportunity.

    Recent Posts

    Leave a Comment